Sarcopenic obesity and physical function in acromegaly: impact of disease control and evaluation using dual X-ray absorptiometry and multifrequency bioelectrical impedance analysis.

Purpose: To assess sarcopenia, sarcopenic obesity, physical performance in patients with acromegaly and compare the diagnostic performance of dual-energy X-ray absorptiometry (DXA) and multifrequency bioelectrical impedance analysis (BIA).

Methods: This cross-sectional study included 27 patients with acromegaly and 27 age-, sex-, and BMI-matched patients without acromegaly. Body composition was assessed using BIA and DXA.

Body Composition, Sarcopenia, and Serum Myokines in Acromegaly: A Narrative Review.

Patients with active acromegaly have a higher percentage of lean body mass, a lower percentage of fat body mass, and an increase in their extracellular water compartment compared to healthy individuals. However, muscle function appears to be compromised in patients with acromegaly, with some experiencing worsened physical performance and sarcopenia. Myokine alterations, insulin resistance, dysregulation of protein metabolism, muscle oxidative stress, neuromuscular junction impairment, and increased ectopic intramuscular fat deposits may play roles in muscle dysfunction in patients with acromegaly.

The Role of Bisphosphonates Prior to Denosumab Treatment on Rebound Fractures: A Mini Review.

Denosumab is a potent anti-resorptive medication used to treat patients at high risk for osteoporosis; however, its beneficial effects on the skeletal system are quickly reversed after discontinuation. In contrast, bisphosphonates (BPs) are anti-resorptive agents with residual effects on the bone matrix; thus, these are capable of preserving bone mass for a long time. Therefore, subsequent anti-resorptive treatment with BPs is mandatory to prevent rebound fractures.